We have evolved from there as a leader in proteomics today. What we ve done is significantly improve and then commercialize this technology. We currently have 130 employees. In 1997 and 1998, we introduced alpha and then beta versions of our products. The outlook that s given right now looks at around 2004 to actually be profitable.
External reasons are the field of proteomics.
We are a pure proteomics play. If you look at the genomics market, particular parts of the world and I ll give you as an example Germany have really kind of missed the boat because of the political environment and the unwillingness to invest for ethical reasons. That is not happening in proteomics. I m back from Japan, Korea and Singapore just recently. So the market itself is very attractive to be active in.